Advertisement

Digestive Diseases and Sciences

, Volume 39, Issue 2, pp 374–380 | Cite as

Efficacy of cyclosporine in treatment of fistula of crohn's disease

  • Daniel H. Present
  • Simon Lichtiger
Originals Articles

Abstract

Sixteen Crohn's disease patients with active fistula who had failed standard medical therapy were treated with intravenous cyclosporine. Ten patients had perirectal disease, four had enterocutaneous fistula, and two had rectovaginal fistula. Patients were initially treated with intravenous cyclosporine, 4 mg/kg/day, and then switched to oral cyclosporine, 6–8 mg/kg/day. Improvement was graded using the Present-Korelitz criteria, and success was defined as moderate to total closure of the fistula. Fourteen of 16 patients (88%) responded in the acute phase to parenteral cyclosporine. Closure of fistula occurred in seven (44%) with moderate improvement in the remaining seven (44%). Subsequently, five patients (36%) relapsed to some degree on oral cyclosporine (three severe and two mild relapses). Nine (64%) patients maintained their improvement in the chronic phase. Chronic steroids could be discontinued in 6/8 (75%) of patients. Mild side effects were common [paresthesias (75%) and hirsuitism (19%)]. A single patient had severe paresthesias requiring discontinuation of therapy. Mild hypertension was noted in four (25%) and one patient (6%) had to be withdrawn because of nephrotoxicity, which reversed after stopping cyclosporine. We conclude that intravenous cyclosporine is effective therapy for perianal, rectovaginal, and enterocutaneous fistula in Crohn's disease. Its future role awaits controlled trials as well as determination of the risk-benefit ratio.

Key words

cyclosporine immunosuppression treatment fistula Crohn's disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Present DH, Korelitz BI, Wisch N, et al: Treatment of Crohn's disease with 6-mercaptopurine. A long-term randomized double blind study. N Engl J Med 302:981–987, 1980Google Scholar
  2. 2.
    Brooke BN, Javett SL, Davison OW: Further experience with azathioprine for Crohn's disease. Lancet 2:1050–1053, 1970Google Scholar
  3. 3.
    Summers RW, Switz DM, Sessions JT Jr: National Cooperative Crohn's Disease Study. Results of drug treatment. Gastroenterology 77:847–869, 1979Google Scholar
  4. 4.
    Kozarek RA, Patterson DJ, Gelfand MD, et al: Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 110:353–356, 1989Google Scholar
  5. 5.
    Binder V, Hendriksen C, Kreiner S: Prognosis in Crohn's disease—based on results from a regional patient group from the county of Copenhagen. Gut 26:146–150, 1985Google Scholar
  6. 6.
    Bernstein LH, Frank MS, Brandt LJ, et al: Healing of perineal Crohn's disease with metronidazole. Gastroenterology 79:357–365, 1980Google Scholar
  7. 7.
    Bunjes D, Hardt C, Rollinghoff M, et al: Cyclosporin mediates immunosuppression of primary cytotoxic T cell response by improving the release of interleukin I and interleukin II. Eur J Immunol 11:657–661, 1981Google Scholar
  8. 8.
    Stange EF, Fleig WE, Rekhlaue E, et al: Cyclosporin A treatment in inflammatory bowel disease. Dig Dis Sci 34:1387–1392, 1989Google Scholar
  9. 9.
    Peltekian KM, Williams CN, MacDonald AS, et al: Open study of cyclosporin A in patients with severe Crohn's disease refractory to conventional therapy. Can J Gastroenterol 2:5–11, 1988Google Scholar
  10. 10.
    Brynskov J, Freund L, Rasmussen SN, et al: A placebo-controlled double blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 321:845–850, 1989Google Scholar
  11. 11.
    MacDermott RP, Stenson WF: The role of the immune system in inflammatory bowel disease. Immunol Allergy Clin North Am 8:521–541, 1988Google Scholar
  12. 12.
    Jones JH, Lennard-Jones JE: Corticosteroids and corticotrophin in the treatment of Crohn's disease. Gut 7:181–187, 1966Google Scholar
  13. 13.
    Spencer JA, Kirsner JD, Mlynaryk P: Immediate and prolonged therapeutic effects of corticotrophin and adrenal steroids in ulcerative colitis. Gastroenterology 42:113–128, 1962Google Scholar
  14. 14.
    Brandt LJ, Bernstein LH, Boley SJ, et al: Metronidazole therapy for perirectal Crohn's disease: A followup study. Gastroenterology 83:383–387, 1982Google Scholar
  15. 15.
    Ursing B, Alm T, Barany F, et al: A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The Cooperative Crohn's Disease Study in Sweden—II. Result. Gastroenterology 83:550–562, 1982Google Scholar
  16. 16.
    Korelitz BI, Present DH: Favorable response of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 30:58–64, 1985Google Scholar
  17. 17.
    Baker WN, Milton-Thompson GJ: Management of anal fistulae in Crohn's disease. Proc R Soc Med 67:58–64, 1974Google Scholar
  18. 18.
    Lichtiger S, Present DH: Preliminary report: Cyclosporine treatment of severe active ulcerative colitis. Lancet 336:16–20, 1990Google Scholar
  19. 19.
    Fukushima T, Sugita A, Masuzawa S, et al: Effect of cyclosporin A on active Crohn's disease. Jpn Soc Gastrenterol 24:12–15, 1989Google Scholar
  20. 20.
    Allam BF, Tillman JE, Thomson TJ, et al: Effective intravenous cyclosporin therapy in a patient with severe Crohn's disease on parenteral nutrition. Gut 28:1166–1169, 1987Google Scholar
  21. 21.
    Sandborn WJ, Strong RM, Forland SC, et al: The pharmacokinetics and colonic tissue concentrations of cyclosporin after IV, oral and enema administration. J Clin Pharmacol 31:76–80, 1991Google Scholar
  22. 22.
    Ellis CN, Gorsulowsky DC, Hamilton TA, et al: Cyclosporin improves psoriasis in a double blind study. JAMA 256:3110–3116, 1986Google Scholar
  23. 23.
    Litzow MR: Multiple responses of aplastic anemia to low dose cyclosporin despite development of myelodysplastic syndrome. Am J Hematol 32:226–229, 1989Google Scholar
  24. 24.
    Friedman AL, Schiffman G, Friedman E: Low dose azathioprine is synergistic with low dose cyclosporin in rabbit skin allograft survival. Transplant Proc 19:1270–1271, 1987Google Scholar

Copyright information

© Plenum Publishing Corporation 1994

Authors and Affiliations

  • Daniel H. Present
    • 1
  • Simon Lichtiger
    • 1
  1. 1.From the Mount Sinai School of MedicineOne Gustave L. Levy PlaceNew York

Personalised recommendations